Latest Apolipoprotein A1 Stories
Two New Research Studies Provide Further Support for the Potential Role of CSL112 in the Reduction of Early Recurrent Cardiovascular Events following Myocardial Infarction KING OF
CSL112 Represents a Promising Investigational Therapy That May Fill a Void in Reducing Early Recurrent Cardiovascular Events in Patients Who Have Suffered a Heart Attack KING OF PRUSSIA, Pa.,
Presented in 'State of the Art and Featured Research Session' at the 2014 European Society of Cardiology Congress TSX Exchange Symbol: RVX BARCELONA, Spain
In addition, preliminary results from an Australian sponsored trial have yet to verify whether the mechanism of RVX-208 action may affect glucose metabolism.
"Most Advanced Epigenetic Drug in Clinical Development" TSX Exchange Symbol: RVX CALGARY, May 21, 2014 /CNW/ - Resverlogix Corp.
"RVX-208 decreases Major Adverse Cardiac Events (MACE) in patients with systemic inflammation" TSX Exchange Symbol: RVX CALGARY, March 31, 2014 /PRNewswire/ - Resverlogix
"European Patent Office Grants RVX-208 Patent Until 2027" "Resverlogix Receives $2.5 Million for Non-Core ApoA-I Assets" TSX Exchange Symbol: RVX CALGARY,
Cleveland Clinic researchers have discovered the process by which high-density lipoprotein (HDL) – the so-called "good cholesterol" – becomes dysfunctional, loses its cardio-protective properties, and instead promotes inflammation and atherosclerosis, or the clogging and hardening of the arteries.
"RVX-208 treated patients have significant lower MACE events in high risk CVD patients" TSX Exchange Symbol: RVX CALGARY, Jan.
TSX Exchange Symbol: RVX CALGARY, Jan. 2, 2014 /PRNewswire/ - Resverlogix Corp.
- A volcanic mudflow.